<?xml version="1.0" encoding="UTF-8"?>
<p>Memantine showed promising anti-Alzheimer effects in preclinical experimental models, however, in clinical studies, it has not shown clear therapeutic efficacy in AD [
 <xref rid="B33-brainsci-10-00964" ref-type="bibr">33</xref>]. It is currently being used in the treatment of moderate to severe AD. The rate of decline in behavioral and functional impairment in patients with moderate to severe AD is reduced by memantine [
 <xref rid="B34-brainsci-10-00964" ref-type="bibr">34</xref>]. Patients taking memantine experience adverse effects like fatigue, pain, confusion, urinary incontinence, urinary tract infection, peripheral edema, etc. [
 <xref rid="B35-brainsci-10-00964" ref-type="bibr">35</xref>]. Thus, the search continues for effective and affordable medicines, which when prescribed for long duration, have acceptable adverse effects or interaction with food and drugs and delay the progression or reverse the disease process.
</p>
